Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shingrix

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

- PMLiVE

GSK gets OK for second quadrivalent flu vaccine in US

FDA approves Flulaval Quadrivalent

- PMLiVE

GSK’s Tyverb cleared for use alongside Herceptin

Combination already approved in the Philippines, Russia and Thailand

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

- PMLiVE

GSK invests $50m in ‘bioelectronic’ medicines

Will support research investigating use of electrical signals in nerves to help treat diseases

- PMLiVE

GSK submits Votrient for ovarian cancer in Europe

Pharma company hopes for extra indication for oncology product

- PMLiVE

GSK loses patent on Tykerb in India

Cuts period of exclusivity by two years

- PMLiVE

GSK’s diabetes hope albiglutide delayed in US

FDA extends deadline to April 2014

- PMLiVE

GSK and Pfizer extend vaccine access programme

Pharma companies lower price of pneumococcal vaccines for developing nations

- PMLiVE

GSK replaces China head as bribery probe rolls on

Herve Gisserot takes over from Mark Reilly

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

National Institute for Health and Care Excellence NICE logo

NICE gives final backing to drugs from Bayer, GSK and Otsuka

Eylea, Revolade and Abilify all recommended for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links